Fingerprint
Dive into the research topics of 'Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Anthony Mills, Gary J. Richmond, Cheryl Newman, Olayemi Osiyemi, Jerry Cade, Cynthia Brinson, Jerome de Vente, David A. Margolis, Kenneth C. Sutton, Viviana Wilches, Sarah Hatch, Jeremy Roberts, Cynthia McCoig, Cindy Garris, Kati Vandermeulen, William R. Spreen
Research output: Contribution to journal › Article › peer-review
15
Scopus
citations